Atria Investments Inc trimmed its stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 15.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Uncover hidden gems in the stock market with the 'Undercovered Dozen' series featuring undervalued stocks with potential for ...

On Thursday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $25.58 which represents a decrease of $-0.27 or -1.04% from the prior close of $25.85. The stock opened at $25.9 and ...

Shares in global vaccine makers and drugmakers fell on Friday after U.S. President-elect Donald Trump picked Robert F.

Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer FoundationThe Prize includes a charitable ...

Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq ... related to a decrease in the Limited Recourse Royalty ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

Good day everyone and welcome to today's Avadel Pharmaceuticals 3Q 2024 Earnings Call. At this time, all participants are in ...

Summit Global Investments acquired a new stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) during the third quarter, ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...